PROROXAN

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H23NO3
Molecular Weight	337.4122
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(CCN1CCC(C1)C2=CC=CC=C2)C3=CC4=C(OCCO4)C=C3

InChI

InChIKey=GZIISXIDAZYOLI-UHFFFAOYSA-N

InChI=1S/C21H23NO3/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16/h1-7,14,18H,8-13,15H2

HIDE SMILES / InChI

Molecular Formula	C21H23NO3
Molecular Weight	337.4122
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://paper.rsmu.ru/pirogovka_2015/articles/article.php?thesis_number=90 | https://www.ncbi.nlm.nih.gov/pubmed/26087584 | http://noillen.bitballoon.com/medicine2/pirroksan-instructio1832

Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 171 Target ID: CHEMBL2094251 Sources: http://paper.rsmu.ru/pirogovka_2015/articles/article.php?thesis_number=90 \| https://www.ncbi.nlm.nih.gov/pubmed/26087584 \| http://dspace.vnmu.edu.ua/bitstream/handle/123456789/1660/General_Pharmacology%20and%20drugs%20affecting%20mediatory%20processes.pdf?sequence=1 \| http://medsideen.bitballoon.com/for-the-nervous-syst102/pirroksan2432.html	Antagonist 2849
Adrenergic receptor alpha-2 114 Target ID: CHEMBL2095158 Sources: http://paper.rsmu.ru/pirogovka_2015/articles/article.php?thesis_number=90 \| https://www.ncbi.nlm.nih.gov/pubmed/26087584 \| http://dspace.vnmu.edu.ua/bitstream/handle/123456789/1660/General_Pharmacology%20and%20drugs%20affecting%20mediatory%20processes.pdf?sequence=1 \| http://medsideen.bitballoon.com/for-the-nervous-syst102/pirroksan2432.html	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 575 Sources: http://drdoping.com/instructions/Proroxan/ http://dspace.vnmu.edu.ua/bitstream/handle/123456789/1660/General_Pharmacology%20and%20drugs%20affecting%20mediatory%20processes.pdf?sequence=1	Primary	Approved 8583	Pirroksan Approved Use Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.
Meniere's disease 16 Sources: http://drdoping.com/instructions/Proroxan/ http://medsideen.bitballoon.com/for-the-nervous-syst102/pirroksan2432.html	Primary	Approved 8583	Pirroksan Approved Use Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.
Motion sickness 43 Sources: http://noillen.bitballoon.com/medicine2/pirroksan-instructio1832 http://medsideen.bitballoon.com/for-the-nervous-syst102/pirroksan2432.html	Primary	Approved 8583	Pirroksan Approved Use Proroxan has been used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429 CYP1A2 2153	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 18.0	inconclusive [IC50 27.5404 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 21.0	inconclusive [IC50 30.9008 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 24.0	inconclusive [IC50 33.4915 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 6.0	no [IC50 9.7717 uM]
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 92.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 2.0	yes [IC50 0.9772 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 92.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/36303#section=Biological-Test-Results Page: 10.0

PubMed

Title	Date	PubMed
[Adrenergic component in the hepatotropic, carcinogenic effect of diethylnitrosamine].	1977-04	15687

Patents

Sample Use Guides

In Vivo Use Guide

Adults: tablets - 20 mg 2-3 times a day; injection - 2-3 ml per day; The maximum daily dose is 90 mg;

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:39:11 GMT 2025` Edited by `admin` on `Mon Mar 31 18:39:11 GMT 2025`
Record UNII	T5WT3QN49G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROROXAN

Official Name

English

proroxan [INN]

Preferred Name

English

1-(1,4-BENZODIOXAN-6-YL)-3-(3-PHENYL-1-PYRROLIDINYL)-1-PROPANONE

Systematic Name

English

1-PROPANONE, 1-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-(3-PHENYL-1-PYRROLIDINYL)-

Systematic Name

English

PROROXAN [MART.]

Common Name

English

1-PROPANONE, 1-(1,4-BENZODIOXAN-6-YL)-3-(3-PHENYL-1-PYRROLIDINYL)-

Systematic Name

English

Proroxan [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29713